When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...

U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker's weaker-than-expected ...

Stocks in Europe ended Monday's session slightly higher, as investors reacted to more disappointing economic news out of the ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Health insurers such as UnitedHealth Group and Cigna also recovered some of their recent losses following public controversy about industry practices in the wake of the assassination of UnitedHealth ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

The study met its main goal, but those watching closely had hoped for an average result of at least 25% weight loss.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Asian and European stock markets were largely getting off to a good start to a holiday-shortened Christmas week. Bargain hunting was in evidence as Novo Nordisk rose following a sharp drop for the ...

However, Novo Nordisk stock opened sharply higher, partially recovering some of Friday's heavy losses after disappointing data for its experimental weight-loss drug CagriSema prompted a selloff. U.S.